Skip to main content

NASAL VACCINATION AGAINST RESPIRATORY INFECTIONS IN YOUNG CHILDREN

Objective

Respiratory infections are the most frequent cause of childhood morbidity and mortality worldwide. For many respiratory pathogens no vaccine is available, for others classical immunisations remain insufficiently effective. This project concerns the development of novel, nasal vaccines against two major respiratory pathogens, B. pertussis and Respiratory Syncytial Virus (RSV). No vaccine is yet available against RSV, and, although efficacious vaccines against pertussis are widely used, roughly 40 million cases and 200,000-400,000 pertussis-linked deaths are recorded annually, mostly in infants (<6 months) not yet sufficiently protected by the current vaccines. This proposal will yield proof of principle and provide prototypes of multivalent nasal vaccines based on attenuated B. pertussis. The concept is based on the fact that early in life, infants can mount strong anti-B. pertussis T cell responses upon natural infection in contrast to vaccination. Live attenuated B. pertussis BPZE1 has already been constructed and shown to be much more protective in infant mice after a single nasal dose than two doses of current pertussis vaccines. Immunity induced by BPZE1 will be studied in detail, and its genetic and biological stability and safety in various mouse models will be characterised. GMP lots of BPZE1 will be produced and tested for safety in a phase 1 trial in adults as a prerequisite to future trials in the target population. In parallel, human immune responses, in particular memory responses to infection and vaccination will be analysed, which will serve as a basis for immunogenic evaluations of BPZE1. Finally, we will develop BPZE1 as a vector for the presentation of heterologous RSV antigens to the respiratory mucosa. This will be tested in mouse models. A successful outcome of this project should lead to further clinical trials with BPZE1 and to the development of multivalent nasal vaccines able to protect against several respiratory pathogens simultaneously.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 956 667
Administrative Contact
Samir Ould Ali (Mr.)

Participants (9)

INSERM TRANSFERT SA
France
EU contribution
€ 310 000
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Louis Jammayrac (Mr.)
UNIVERSITE LIBRE DE BRUXELLES
Belgium
EU contribution
€ 480 000
Address
Avenue Franklin Roosevelt 50
1050 Bruxelles
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Françoise Mascart (Prof.)
ISTITUTO SUPERIORE DI SANITA
Italy
EU contribution
€ 450 000
Address
Viale Regina Elena 299
00161 Roma
Activity type
Research Organisations
Administrative Contact
Rosa Maria Martoccia (Dr.)
NATIONAL UNIVERSITY OF IRELAND MAYNOOTH
Ireland
EU contribution
€ 370 000
Address
Co Kildare
W23 Maynooth
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mike O’malley (Mr.)
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 450 000
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mike Robinson (Mr.)
SMITTSKYDDSINSTITUTET
Sweden
EU contribution
€ 900 000
Address
Nobels Vaeg 18
17182 Solna
Activity type
Research Organisations
Administrative Contact
Bengt-åke Andersson (Mr.)
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU
Netherlands
EU contribution
€ 250 000
Address
Antonie Van Leeuwenhoeklaan 9
3721 MA Bilthoven
Activity type
Research Organisations
Administrative Contact
Marjon Straver (Ms.)
INNOGENETICS NV
Belgium
EU contribution
€ 633 333
Address
Technologiepark 6
9052 Zwijnaarde
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Annie Van Broekhoven (Dr.)
MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT

Participation ended

Netherlands
EU contribution
€ 200 000
Address
Parnassusplein 5
2500 EJ Den Haag
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Erik P.J. Popping (Mr.)